Table 2.

Baseline characteristics of the patients.

CharacteristicsAll Patients, n = 82Patients with Infusion Reactions, n = 14Patients without Infusion Reactions, n = 68
Female, n (%)59 (72)12 (86)47 (69)
Diagnosis, n (%)
  JIA70 (85)14 (100)56 (81)
    Persistent oligoarthritis/extended oligoarthritis30426
    Polyarthritis (RF-negative)24717
    Polyarthritis (RF-positive)101
    Enthesitis-related arthritis303
    Psoriatic arthritis110
    Systemic arthritis514
    Undifferentiated arthritis615
  Ocular inflammatory disease10 (12)010 (15)
  Other inflammatory disease2 (2)02 (3)
    Unclassified systemic inflammatory disease11
    Takayasu arteritis11
Comorbid conditions, n (%)16 (20)3 (21)13 (19)
  Genetic diseases (e.g., trisomy 21, Williams-Beuren syndrome)615
  Autoimmune diseases (e.g., linear SSc, Crohn disease)404
  Other (e.g., osteochondritis dissecans, attention deficit disorder)624
Indication for IFX (%)
  Arthritis49 (60)12 (86)37 (54)
  Uveitis16 (20)016 (24)
  Arthritis and uveitis13 (16)2 (14)11 (16)
  Other4 (5)04 (6)
    Crohn disease and JIA11
    Systemic JIA11
    Unclassified systemic inflammatory disease11
    Takayasu arteritis11
Comedication, n (%)
  MTX67 (82)11 (79)56 (82)
  Leflunomide8 (10)2 (14)6 (9)
  MTX, then leflunomide4 (5)04 (6)
  MTX, then azathioprine01 (7)0
  Sulfasalazine1 (1)01 (1)
  Azathioprine1 (1)01 (1)
Previous biologicals, n (%)21 (26)3 (21)18 (26)
Age at IFX start, yrs, mean ± SD10.1 ± 3.98.2 ± 4.210.5 ± 3.7
  Range2.3–17.02.3–16.93.7–17.0
Disease duration at IFX start, yrs, mean ± SD3.9 ± 3.32.9 ± 2.24.1 ± 3.5
  Range0.2–14.70.7–7.00.2–14.7
Followup during study period, wks, mean ± SD169 ± 136.6173 ± 175.2168.3 ± 128.8
  Range3–56018–5600–545.4
Number of infusions, mean ± SD30 ± 2030 ± 290
  Range2–1146–114
Dose of IFX, mg/kg/dose, mean ± SD6.2 ± 1.55.5 ± 1.7*6.3 ± 1.5
  Range3.5–10.43.5–8.53.5–10.4
Infusion interval of IFX, wks, mean ± SD5.2 ± 1.35.0 ± 1.3*5.3 ± 1.4
  Range2.2–15**2.9 ± 7.02.2–15**
  • * Calculated from beginning of IFX treatment to first infusion reaction.

  • ** Usually we discontinued treatment after maximum infusion interval of 12 weeks. The long interval of 15 weeks was due to retardation caused by viral illness. IFX: infliximab; RF: rheumatoid factor; SSc: systemic sclerosis; MTX: methotrexate.